Novel Biomarker Discovery for Diagnostic and Therapeutic Strategies in Prostate Cancer
Abstract
The purpose of this grant is to identify, isolate and characterize high affinity aptamers that distinguish between prostate cancers that are likely to remain organ-confined and those with potential to metastasize, The scope of this pilot is to generate DNA aptamers that selectively react with a prostate cancer cell line that remains confined to the prostate (LNCaP) vs. a subpopulation of this cell line that has acquired the ability to metastasize aggressively, employing Cell-Selex and Aptamer-Facilitated Biomarker Discovery (AptaBiD) technology. Major Findings and Progress: (1) Non-metastatic LNCaP-Pro-5 cells and metastatic LNCaP-LN3 cells have been provided by Curtis Pettaway, M.D. Anderson Cancer Center, Houston, Texas. (2) Parental LNCaP cells have been obtained from American Type Culture Collection. (3) Phenotypic validation (aggressive vs. indolent growth) has been carried out on all cell lines using the Boyden Chamber assay. (4) DNA 40 bp aptamer libraries have been generated. (5) The first of 8 rounds of Cell-Selex has been initiated. (6) Plan for next-generation sequencing and bioinformatic analysis pathway has been established to yield desired phenotype-specific DNA aptamers. Next steps will include completion of Cell-Selex, NexGen sequencing and testing of DNA aptamer families on human clinical prostate cancer specimens.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2013
- Accession Number
- ADA604489
Entities
People
- Betty Diamond
- Nanette H. Bishopric
Organizations
- University of Miami